796 related articles for article (PubMed ID: 31219975)
21. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
Nagler A; Perriello VM; Falini L; Falini B
Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
[TBL] [Abstract][Full Text] [Related]
22. Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.
Yu L; Zou R; He J; Qu C
Crit Rev Oncol Hematol; 2024 Jul; 199():104390. PubMed ID: 38782146
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Mu J; Deng H; Lyu C; Yuan J; Li Q; Wang J; Jiang Y; Deng Q; Shen J
Hematol Oncol; 2023 Apr; 41(2):275-284. PubMed ID: 35195933
[TBL] [Abstract][Full Text] [Related]
24. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
Front Immunol; 2021; 12():665230. PubMed ID: 33953727
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
27. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
29. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
30. Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma.
Yu Q; Zhang X; Wang N; Li C; Zhang Y; Zhou J; Wang G; Cao Y
Radiother Oncol; 2022 Dec; 177():53-60. PubMed ID: 36309153
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
32. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
Eigendorff F; Filimonova I; Scholl S; Sayer-Klink A; Rummler S; Kunert C; Pietschmann K; Wittig A; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2024 May; 150(5):224. PubMed ID: 38693452
[TBL] [Abstract][Full Text] [Related]
33. Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report.
Chen HH; Kuo CY; Ho CL; Chen YC
Medicine (Baltimore); 2023 Oct; 102(41):e35432. PubMed ID: 37832125
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
[No Abstract] [Full Text] [Related]
35. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
[TBL] [Abstract][Full Text] [Related]
36. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
38. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.
Gong IY; Aminilari M; Landego I; Hueniken K; Zhou Q; Kuruvilla J; Hodgson DC
Leuk Lymphoma; 2023 Oct; 64(10):1643-1654. PubMed ID: 37548344
[TBL] [Abstract][Full Text] [Related]
40. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
